Hologic (NASDAQ:HOLX - Get Free Report) was downgraded by equities researchers at Leerink Partnrs from a "strong-buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for Hologic's Q3 2025 earnings at $1.10 EPS, FY2025 earnings at $4.27 EPS, Q1 2026 earnings at $1.14 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.17 EPS, FY2026 earnings at $4.60 EPS and FY2027 earnings at $4.88 EPS.
A number of other equities research analysts also recently commented on the company. Wolfe Research assumed coverage on Hologic in a research report on Friday, December 13th. They set a "peer perform" rating for the company. William Blair reiterated an "outperform" rating on shares of Hologic in a research report on Thursday. Mizuho reduced their price objective on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating for the company in a research note on Tuesday, November 5th. Royal Bank of Canada dropped their target price on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research report on Thursday. Finally, Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday. Ten research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $85.77.
Check Out Our Latest Stock Report on HOLX
Hologic Price Performance
Shares of NASDAQ:HOLX traded up $0.39 during trading on Thursday, reaching $64.97. The company had a trading volume of 1,961,384 shares, compared to its average volume of 2,560,402. The firm's fifty day moving average is $72.33 and its 200 day moving average is $77.76. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.03 and a current ratio of 3.49. The firm has a market capitalization of $14.66 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic has a twelve month low of $63.62 and a twelve month high of $84.67.
Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts forecast that Hologic will post 4.27 EPS for the current year.
Insider Activity
In other news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.88% of the stock is owned by company insiders.
Institutional Investors Weigh In On Hologic
A number of hedge funds have recently added to or reduced their stakes in the stock. Wolff Wiese Magana LLC acquired a new position in shares of Hologic during the third quarter worth approximately $25,000. General Partner Inc. acquired a new position in Hologic during the 4th quarter worth $26,000. Venturi Wealth Management LLC boosted its position in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after buying an additional 261 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Finally, Cromwell Holdings LLC raised its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 416 shares during the last quarter. Institutional investors own 94.73% of the company's stock.
Hologic Company Profile
(
Get Free Report)
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.
Further Reading
Before you consider Hologic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hologic wasn't on the list.
While Hologic currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
